SSBH 2026

Day 3 June 20(Sat) 09:00-10:00	Oral Presentation 3 [Clinical] Room 1

Chair(s): Kyung-Ah Jeong (Ewha Womans University, Korea), Yunkyung Jeon (Pusan National University, Korea)

09:00-09:10	Incidence and Risk Factors of Denosumab-Induced Hypocalcemia in Women with Acute Distal Radius Fracture Using a Standardized Screening Protocol Hwang Ji Sup (Seoul National University, Korea)
09:10-09:20	Associations of Gait Speed, Grip Strength, Depressive Symptoms, and their Combinations with Fracture Risk in Older Adults Temam Beshir Raru (Deakin University, Australia)
09:20-09:30	Gluteofemoral Fat Increases Fracture Risk Mediated by Reduced Bone Mineral Density in Two-sample Medelian Randomization Study Da Yeon Jang (Seoul National University, Korea)
09:30-09:40	Prospective, Observational Study of the Real-World Safety of Romosozumab in Patients with Osteoporosis in South Korea Yumie Rhee (Yonsei University, Korea)
09:40-09:50	Association of Smoking Patterns Including Electronic Cigarette and Dual use with Incident Osteoporotic-Site Fracture in Korean Adults: a linked KNHANES-HIRA Cohort Study Jahye Jung (Ewha Womans University, Korea)
09:50-10:00	Comparative Analysis of Early Transition from Romosozumab to Denosumab in Surgically Treated Hip Fracture Patients: A Propensity Score-Matched Retrospective Study Si Hyun Kim (Inje University, Korea)
10:00-10:10	Association of Insulin Resistance and Fracture Risk in the Osteoporotic Fractures in Men (MrOS) Cohort Jeonghoon Ha (The Catholic University of Korea, Korea)

Day 3 June 20(Sat) 10:15-11:00	Plenary Lecture 3 Room 1

We are privileged to welcome Professor Dennis M. Black from the University of California, San Francisco (UCSF), as a Plenary Speaker for SSBH 2026. A towering figure in the field of osteoporosis clinical trials, Professor Black has been the lead investigator for several landmark studies that have shaped current treatment guidelines. In this lecture, he will present the transformative findings of the SABRE (Study to Advance BMD as a Regulatory Endpoint) Project. The SABRE project is a monumental effort that addressed a decades-long challenge in drug development: the necessity of long-term fracture trials for new drug approval. By analyzing data from over 160,000 participants across dozens of clinical trials, Professor Black and his team established Bone Mineral Density (BMD) change as a validated surrogate endpoint for fracture risk reduction. This breakthrough led to the historic 2025 FDA qualification of BMD as a primary regulatory endpoint, significantly accelerating the pathway for future osteoporosis therapies. In this session, Professor Black will detail the rigorous statistical framework of SABRE and discuss how these results will catalyze the development of next-generation bone-forming agents and combination therapies.

Chair(s): Ki-Hyun Baek (The Catholic University of Korea, Korea)

10:15-11:00	The Coming Cascade of New Osteoporosis Treatments: Implications of FDA Qualification of BMD Change to Replace Fracture Risk as the Trial Endpoint for New Osteoporosis Therapies Dennis M Black (University of California, San Francisco, USA)

Day 3 June 20(Sat) 11:15-12:30	Symposium 4. Optimizing Treatment Strategies with Anabolic Agents Room 1

This symposium provides a focused and clinically oriented examination of anabolic therapies for osteoporosis, bringing together experts from Japan and Korea to address the therapeutic landscape, safety considerations, and long-term management strategies surrounding this drug class. Dr. Kosuke Ebina (Osaka University) opens with a comparative review of the three available anabolic agents, teriparatide, abaloparatide, and romosozumab, evaluating their mechanisms, efficacy profiles, and practical positioning in treatment algorithms. Dr. Seong Hee Ahn (Inha University) then addresses one of the most actively debated issues in the field, synthesizing current evidence on the cardiovascular safety of anabolic agents, navigating ongoing controversies, and translating findings into real-world clinical decision-making. The symposium concludes with Dr. Namki Hong (Yonsei University) examining the longer view of how anabolic agents can be optimally deployed within sequential and combination treatment strategies to sustain skeletal benefits over time. Together, these presentations equip clinicians with a nuanced, evidence-based framework for optimizing anabolic therapy across the full arc of osteoporosis management.

Chair(s): Yumie Rhee (Yonsei University, Korea), Yong Jun Choi (Ajou University, Korea)

11:15-11:40	The Anabolic Trio: Comparative Review of Teriparatide, Abaloparatide, and Romosozumab Kosuke Ebina (Osaka University, Japan)
11:40-12:05	Cardiovascular Safety of Anabolics: Evidence, Controversies, and Real-World Implications Seong Hee Ahn (Inha University, Korea)
12:05-12:30	Anabolics in Long-Term Osteoporosis Treatment: Sequential and Combination Strategies Namki Hong (Yonsei University, Korea)

Day 3 June 20(Sat) 12:30-12:45	Luncheon Symposium 3 Room 1

Chair(s): Kyuri Hwang (Seoul National University, Korea)

12:30-12:45	Efficacy & Safety from a Global Phase 3 Trial Including Korean: Obodence Hye Sun Park (Yonsei University, Korea)

Day 3 June 20(Sat) 13:30-14:40	Oral Presentation 5 [Clinical] Room 1

Chair(s): Seung-Hoon Baek (Kyungpook National University, Korea), Bukyung Kim (Kosin University, Korea)

13:30-13:40	Sex-Specific Long-term Fracture Risk and Cortisol-Dependent Associations in Mild Autonomous Cortisol Secretion: A Cohort Study With National Health Insurance Linkage Seung Shin Park (Seoul National University, Korea)
13:40-13:50	Associations between Acrylamide Exposure and Risk of Low Skeletal Muscle Mass: Evidence from NHANES 2013-2018 Kun-Hee Oh (Seoul National University, Korea)
13:50-14:00	Differential Skeletal Response to Parathyroidectomy Across Biochemical Phenotypes of Primary Hyperparathyroidism Sung Joon Cho (Catholic Kwandong University, Korea)
14:00-14:10	Denosumab Therapy Beyond 10 years: Subsequent Treatment and Densitometric Outcomes Wong Chun Ho (The University of Hong Kong, Hong Kong)
14:10-14:20	Parity, Cumulative Hormonal Exposure, and Skeletal Health in Postmenopausal Women: Findings from the Korea National Health and Nutrition Examination Survey Kyunghun Sung (The Catholic University of Korea, Korea)
14:20-14:30	Multicenter RCT on the Effects of Exercise-Nutrition Intervention for Sarcopenia Patients with Hip Fractures in Korean Adults Yong-Chan Ha (Seoul Bumin Hospital, Korea)
14:30-14:40	Physical Function and Health-Related Quality of Life Across Osteoporosis, Sarcopenia, and Osteosarcopenia: A Cross-Sectional Study from the 2024 KNHANES Seungjin Baek (Yonsei University, Korea)

Day 3 June 20(Sat) 14:55-16:10	Symposium 6. Transforming Bone Health with Artificial Intelligence and Deep Learning Room 1

This symposium explores the transformative potential of artificial intelligence and deep learning in reshaping how we assess, predict, and manage skeletal disease. The session opens with Dr. Kyoung Min Kim (Yonsei University) presenting on precision medicine, examining how AI-driven models can predict individual treatment responses in osteoporosis and move clinical decision-making beyond one-size-fits-all approaches. Dr. Sung Hye Kong (Seoul National University) then broadens the scope to musculoskeletal integration, demonstrating how combining muscle and bone metrics rather than relying on bone density alone can meaningfully improve fracture risk stratification. The symposium concludes with Dr. Keisuke Uemura (Osaka University) showcasing automated screening tools that leverage CT images and conventional X-rays to detect osteoporosis and skeletal muscle loss at scale. Together, these three presentations chart a coherent trajectory from individualized treatment optimization to population-level screening, unified by the power of AI to extract clinically actionable information from imaging data.

Chair(s): Keeho Song (Konkuk University, Korea), Kyong Wook Yi (Korea University, Korea)

14:55-15:20	Precision Medicine in Osteoporosis: Applying AI in Predicting Treatment Response Kyoung Min Kim (Yonsei University, Korea)
15:20-15:45	Integrating Muscle and Bone Metrics for Improving Fracture Risk Assessment Sung Hye Kong (Seoul National University, Korea)
15:45-16:10	Screening for Osteoporosis and Skeletal Muscle Loss Using CT Images and X-Rays Keisuke Uemura (Osaka University, Japan)

Scientific Program